secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2025-04-22T23:59:59+00:00
Accession:  0001645113-25-000007
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure's Optune Lua receives CE Mark for metastatic NSCLC treatment
---------------------------------------------------------------------

- CE Mark for Optune Lua in mNSCLC with immune checkpoint inhibitors or docetaxel after platinum progression.
- Phase 3 LUNAR trial: median OS 13.2 months (Optune Lua) vs 9.9 months (control); primary endpoint met.
- Subgroup with immune checkpoint inhibitor: median OS 18.5 vs 10.8 months (P=0.03).
- Local registration initiated in Germany; launch expected in coming weeks. FDA approval received Oct 2024.
- Post-market study of TTFields with docetaxel required as condition; 180 patients, 12-month follow-up.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000007/0001645113-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000007/nvcr-20250422.htm
  HTML page:      https://secwatch.observer/filing/0001645113-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer